Studies for people living with HIV
Active studies related to HIV cure science (including therapeutic vaccines) are conducted by the AIDS Clinical Trials Group (ACTG) at the Positive Health Program at the University of California, San Francisco.
For more information about the actively enrolling studies below please call or text Dan Berrner at (415) 535-9495 or email him at firstname.lastname@example.org.
Currently enrolling studies:
A5369 – Vaccine Study
This study evaluates the safety and effectiveness of a new vaccine in HIV infected persons. It will look at whether an anti-HIV vaccine is safe and effective and whether it improves immune responses in people infected with HIV. The vaccine, which is a therapeutic or treatment vaccine, is not meant to prevent HIV infection but rather to improve how a person’s immune system responds to HIV infection. Participation will consist of about 6 study visits over the course of 48 weeks. People between the ages of 18–65 years old may be eligible. Compensation starts at $50 per visit.
A5357 – Long-Acting Cabotegravir Plus Antibody
This study will evaluate the safety and effectiveness of an anti-HIV injectable drug called Cabotegravir combined with the addition of an antibody called a “broadly neutralizing monoclonal antibody”. It will look at whether the combination is safe, how it is processed through a person’s body, and if it reduces HIV viral load. Participation will be conducted in 3 steps and will begin with pills taken orally and then change to receiving medication by injection and intravenous infusion. Participation can be as short as 3 visits over 4 weeks or as long as 24 visits over 22 months and depends upon your specific group assignments. Most people will complete all 24 visits. This study would require you to discontinue your current ART to initiate Cabotegravir plus the broadly neutralizing antibody. People over the age of 18 may be eligible. Compensation starts at $50 per visit.
A5370 – Anti-PD1 Antibody (Cemiplimab)
Anti-PD-1 is a type of antibody that may target certain cells where HIV hides called “latently infected cells”. It may improve the body’s ability to clear these cells, allowing for the possibility of reducing the amount of HIV that persists in a body (called the HIV reservoir). This study is evaluating whether Cemiplimab is safe and effective at targeting these hidden cells infected with HIV. If you join the study, you will receive 2 infusion doses of Cemiplimab, one at the beginning and another 6 weeks later. There will be 16 visits over 48 weeks. People over the age of 18 may be eligible. Compensation starts at $50 per visit.
A5377 – Tri-specific Broadly Neutralizing Antibody (bNAbs)
This study will evaluate the safety and tolerability of an antibody provided by intravenous infusion. Antibodies that develop naturally against HIV attach to one part of the virus so that the body’s immune system can try to attack it. Antibodies are usually made by a person’s own immune system, but they can also be developed like a drug. The antibody this study is using has been developed to attach to three parts of the HIV virus at the same time and to neutralize (or block) the ability of the virus to infect more cells. The purpose of the study is to evaluate the product at different doses. Participation will include multiple infusion visits and can range from 11 visits over 24 weeks or as long as 28 visits over 16 months, depending upon your specific group assignment. People over the age of 18 may be eligible. Compensation starts at $50 per visit.